The pharmaceutical firm will pay $425m up-front for University of Michigan and Ohio State University-founded OncoImmune after the latter pivoted its research pipeline to target severe cases of covid-19.

OncoImmune, a US-based covid-19 treatment developer leveraging University of Michigan and Ohio State University research, is set to be acquired by drug developer Merck & Co in a $425m all-cash transaction. Merck & Co will acquire OncoImmune through a subsidiary subject to customary regulatory conditions, with the deal anticipated to close before the end of…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.